Safety Considerations with Pharmacological Treatment of Gestational Diabetes Mellitus

Drug Safety

Volumn 38, Issue 1, 2015, Pages 65-78

  Simmons, David ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN LISPRO; MEGLITINIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

BLOOD GLUCOSE MONITORING; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED; DIABETES, GESTATIONAL; DRUG EFFECTS; FEMALE; LIFESTYLE;

ANIMALS; BLOOD GLUCOSE; DIABETES, GESTATIONAL; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIFE STYLE; METFORMIN; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925485802     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0253-9     Document Type: Review

References (113)

1. Vallance P. Drugs and the fetus. BMJ. 1996;312:1053–4.
2. Freinkel N. Banting lecture 1980. Of pregnancy and progeny. Diabetes. 1980;29:1023–35.
3. Franks PW, Looker HC, Kobes S, Touger L, Tataranni PA, Hanson RL, et al. Gestational glucose tolerance and risk of type 2 diabetes in young Pima Indian offspring. Diabetes. 2006;55:460–5.
4. Lawlor DA, Lichtenstein P, Långström N. Association of maternal diabetes mellitus in pregnancy with offspring adiposity into early adulthood: sibling study in a prospective cohort of 280,866 men from 248,293 families. Circulation. 2011;123:258–65.
5. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.
6. Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. Lancet. 2002;359:1690–2.
7. Ferrara A. Increasing prevalence of gestational diabetes: a public health perspective. Diabetes Care. 2007;30(Suppl 2):S141–6.
8. Lawrence JM, Chen W, Contreras R, Sacks D. Trends in the prevalence of pre-existing diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women 1999–2005. Diabetes Care. 2008;31:899–904.
9. Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care. 2008;31:340–6.
10. Pettitt DJ, Aleck KA, Baird HR, Carraher MJ, Bennett PH, Knowler WC. Congenital susceptibility to NIDDM. Role of intrauterine environment. Diabetes. 1988;37:622–8.
11. Plagemann A, Harder T, Kohlhoff R, Rohde W, Dorner G. Glucose tolerance and insulin secretion in children of mothers with pregestational IDDM or gestational diabetes. Diabetologia. 1997;40:1094–100.
12. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115:e290. doi:10.1542/peds.2004-1808.
13. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS, Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352:2477–86.
14. Landon M, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361:11–20.
15. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, MiG Trial Investigators. Metformin vs insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003–15.
16. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;19(343):1134–8.
17. Simmons D, Robertson S. Influence of maternal insulin treatment on the infants of women with gestational diabetes. Diabet Med. 1997;14:762–5.
18. Hillier TA, Pedula KL, Schmidt MM, Mullen JA, Charles MA, Pettitt DJ. Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycaemia. Diabetes Care. 2007;30:2287–92.
19. Gillman MW, Oakey H, Baghurst PA, Volkmer RE, Robinson JS, Crowther CA. Effect of treatment of gestational diabetes mellitus on obesity in the next generation. Diabetes Care. 2010;33:964–8.
20. The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1999–2002.
21. World Health Organisation. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy WHO/NMH/MND/13.2. Geneva: WHO; 2013. http://apps.who.int/iris/bitstream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf. Accessed 1 July 2014.
22. Nachum Z, Ben-Shlomo I, Weiner E, Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ. 1999;319:1223–7.
23. De Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237–41.
24. Horvath K, Koch K, Jeitler K, Matyas E, Bender R, Bastian H, et al. Effects of treatment in women with gestational diabetes mellitus: systematic review and meta-analysis. BMJ. 2010;340:c1395. doi:10.1136/bmj.c1395.
25. IADPSG Consensus Panel. International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–82.
26. Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon M. Glycemic control in gestational diabetes mellitus: how tight is tight enough; small for gestational age versus large for gestational age? Am J Obstet Gynecol. 1989;161:646–53.
27. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 2013;35(7):595–601.
28. Simmons D. Diabetes and obesity in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:25–36.
29. Ludwig DS, Currie J. The association between pregnancy weight gain and birthweight: a within-family comparison. Lancet. 2010;376:937–8.
30. Schack-Nielsen L, Michaelsen KF, Gamborg M, Mortensen EL, Sørensen TI. Gestational weight gain in relation to offspring body mass index and obesity from infancy through adulthood. Int J Obes. 2010;34:67–74.
31. Olson CM, Strawderman MS, Dennison BA. Maternal weight gain during pregnancy and child weight at age 3 years. Matern Child Health J. 2009;13:839–46.
32. Wrotniak BH, Shults J, Butts S, Stettler N. Gestational weight gain and risk of overweight in the offspring at age 7 y in a multicenter, multiethnic cohort study. Am J Clin Nutr. 2008;87:1818–24.
33. Oken E, Rifas-Shiman SL, Field AE, Franzier AL, Gillman MW. Maternal gestational weight gain and offspring weight in adolescence. Obstet Gynecol. 2008;112:999–1006.
34. Mamun AA, O’Callaghan M, Callaway L, Williams G, Najman J, Lawlor DA. Associations of gestational weight gain with offspring body mass index and blood pressure at 21 years of age: evidence from a birth cohort study. Circulation. 2009;119:1720–7.
35. Laitinen J, Jääskeläinen A, Hartikainen A, Sovio U, Vääräsmäki M, Pouta A, et al. Maternal weight gain during the first half of pregnancy and offspring obesity at 16 years: a prospective cohort study. BJOG. 2012;119:716–23.
36. Jensen DM, Oversen P, Beck-Nielsen H, Mølsted-Pedersen L, Sørensen B, Vinter C, et al. Gestational weight gain and pregnancy outcomes in 481 obese glucose-tolerant women. Diabetes Care. 2005;28:2118–22.
37. Herring SJ, Rose MZ, Skouteris H, Oken E. Optimizing weight gain in pregnancy to prevent obesity in women and children. Diabetes Obes Metab. 2012;14:195–203.
38. Simmons D, Thompson CF, Conroy C, Scott DJ. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care. 2001;24:2078–82.
39. Jackson WPU, Campbell GD, Notelovitz M, Blumsohn D. Tolbutamide and chlorpropamide during pregnancy in human diabetics. Diabetes. 1962;11(suppl):98–103.
40. Torlone E, Di Cianni G, Mannino D, Lapolla A. Insulin analogs and pregnancy: an update. Acta Diabetologica. 2009;46:163–72.
41. Chenoweth H, Probert H. Observational outcome data using glulisine during pre-conception and throughout pregnancy in women with type 1 diabetes. Diabet Med. 2014;31(suppl 1):P180.
42. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151–67.
43. Rönnemaa T, Viikari J. Reducing snacks when switching from conventional soluble to lispro insulin treatment: effects on glycaemic control and hypoglycaemia. Diabet Med. 1998;15:602–7.
44. Home PD, Lindholm A, Hylleberg A, Round P, UK Insulin Aspart Group. Improved glycemic control with insulin aspart. Diabet Care. 1998;21:1904–9.
45. Home PD, Lindholm A, Riist A, European Insulin Aspart Study Group. Insulin aspart vs human insulin in the management of long term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17:762–70.
46. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time action profile of the long acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:6440–9.
47. Ratner RE, Mecca TE, Hirsch IB, Wilson CA, Neifing JL, Garg SK. Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23:639–43.
48. Rosenstock J, Donley DW, Schwartz SL, Edwards MB, Clark CM, Park GD. Basal insulin therapy in type 2 diabetes. Diabetes Care. 2001;24:631–6.
49. Mathiesen ER, Damm P, Jovanovic L, McCance DR, Thyregod C, Jensen AB, et al. Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised, controlled trial in type 1 diabetes. Diabetes Metab Res Rev. 2011;27:543–51.
50. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy. Diabetes Care. 2010;33:29–33.
51. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614–20.
52. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47(4):622–9.
53. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26(5):724–36.
54. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008;25(4):442–9.
55. Hod M, McCance DR, Ivanisevic M, Duran-Garcia S, Jovanovic L, Mathiesen ER, et al. Perinatal outcomes in a randomised trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes [abstract no. 62-LB]. ADA annual scientific conference; 24–28 Jun 2011; San Diego.
56. Jovanovic L. Point: oral hypoglycaemic agents should not be used to treat diabetic women. Diabetes Care. 2007;30:2976–9.
57. Balani J, Hyer SL, Rodin DA, Shehata H. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: case control study. Diabet Med. 2009;26:798–802.
58. National Institute for Health and Clinical Excellence. NICE clinical guideline 63. Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period. London: National Institute for Health and Clinical Excellence; 2008.
59. Vanky E, Zahlsen K, Sprigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83:1575–8.
60. Hague WM, Davoran PH, McIntyre D, Norris R, Xiaonian X, Charles B. Metformin crosses the placenta: a modulator for fetal insulin resistance. BMJ. 2003;327:880–1.
61. Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycaemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol. 1994;171:653–60.
62. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med. 2000;17:507–11.
63. Hughes RCE, Rowan JA. Pregnancy in women with type 2 diabetes: who takes metformin and what is the outcome? Diabet Med. 2006;23:318–22.
64. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod. 2004;19:1323–30.
65. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34:2279–84.
66. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542–6.
67. Hughes RCS, Gardiner SJ, Begg EJ, Zhang M. Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med. 2006;23:323–326.
68. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25:515–29.
69. Gao H, Xiao W, Wang C, Zhang J, Yang Y, Yang J, et al. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study. Int J Clin Pract. 2008;62:695–700.
70. Scale T, Harvey JN. Diabetes, metformin and lactic acidosis. Clin Endocrinol. 2011;74:191–6.
71. 12 status of patients on long-term metformin therapy. Br Med J. 1971;2:685–7.
72. Ting RZW, Szeto CC, Ho-Ming Chan M, Ma KK, Chow KM. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med. 2006;166:1975–9.
73. Carlsen SM, Kjotrod S, Vanky E, Romundstad P. Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. Acta Obstet Gynecol. 2007;86:145–50.
74. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, et al. Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia. 2008;51:29–38.
75. Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF. Transfer of metformin into human milk. Diabetologia. 2002;45:1509–14.
76. Gardiner SJ, Kirkpatrick CM, Begg EJ, Zhang M, Moore MP, Saville DJ. Transfer of metformin into human milk. Clin Pharmacol Ther. 2003;73:71–7.
77. Fanelli CG, Bolli GB. Sulphonylureas and pregnancy. Eur J Endocrinol. 1998;138:615–6.
78. Benz J. Antidiabetic agents and lactation. J Hum Lact. 1992;8:27.
79. Feig DS, Briggs GG, Kraemer JM, Ambrose PJ, Moskovitz DN, Nageotte M, et al. Transfer of glyburide and glipizide into breast milk. Diabetes Care. 2005;28:1851–5.
80. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol. 2004;18:619–21.
81. Kolagasi O, Sari F, Akar M, Sari R. Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy. Ann Pharmacother. 2009;43:147–9.
82. Gaal Z, Klupa T, Kamtor I, Mlynarski W, Albert L, Tolloczko J, et al. Sulfonylurea use during entire pregnancy in diabetes because of KCNJ11 mutation: a report of two cases. Diabetes Care. 2012;35:e40.
83. Amaryl Product Monograph 2009. http://products.sanofi.ca/en/amaryl.pdf. Accessed 8 April 2012.
84. Kwak DW, Choi J-S. A case of term delivery with diagnosis of severe oligohydramnios after exposure to glimepiride, metformin and antihypertensive agents including angiotensin receptor antagonist up to approximately 20 weeks of pregnancy. Korean J Perinatal. 2013;24:95–100.
85. Holt RIG, Clarke P, Parry EC, Coleman MAG. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes Obes Metab. 2008;10:906–11.
86. Ogunyemi DA, Fong A, Rad S, Fong S, Kjos SL. Attitudes and practices of healthcare providers regarding gestational diabetes: results of a survey conducted at the 2010 meeting of the International Association of Diabetes in Pregnancy Study Group (IADPSG). Diabet Med. 2011;28:976–86.
87. Elliott BD, Langer O, Schenker S, Johnston RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;165:807–12.
88. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343:1134–8.
89. Koren G. Glyburide and fetal safety: transplacental pharmacokinetic considerations. Reprod Toxicol. 2001;15:227–9.
90. Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GDV, Obstetric-Fetal Pharmacology Research Unit Network, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009;85:607–14.
91. Schwartz R, Rosenn B, Aleksa K, Koren G. Transplacental transfer of glyburide: is it clinically significant? Am J Obstet Gynecol. 2013;208(Suppl 1):S25.
92. Moretti ME, Rezvani M, Koren G. Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes. Ann Pharmacother. 2008;42:483–90.
93. Moore TR. Glyburide for the treatment of gestational diabetes. A critical appraisal. Diabetes care. 2007;30(Suppl 2):S209–13.
94. Cheng YW, Chung JH, Block-Kurbisch I, Inturrisi M, Caughey AB. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J Matern Fetal Neonatal Med. 2012;25:379–84.
95. Simmons D. Metformin treatment for type 2 diabetes in pregnancy? Best Pract Res Clin Endocrinol Metab. 2010;24:625–34.
96. Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol. 2011;25:51–63.
97. Ekpebegh CO, Coetzee EJ, van der Merwe L, Levitt NS. A 10 year retrospective analysis of pregnancy outcome in pregestational type 2 diabetes: comparison of insulin and oral glucose lowering agents. Diabet Med. 2007;24:253–8.
98. Mollar-Puchades MA, Martin-Cortes A, Perez-Calvo A, Diaz-Garcia C. Use of repaglinide on a pregnant woman during embryogenesis. Diabetes Obes Metab. 2007;9:146–7.
99. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507–14.
100. Froment P, Gizard F, Staels B, Dupont J, Monget P. A role of PPAR gamma in reproduction? Med Sci. 2005;21:507–11.
101. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585–95.
102. Schaiff W, Carlson MG, Smith SD, Levy R, Nelson DM, Sadovsky Y. Peroxisome proliferator-activated receptor-gamma modulates differentiation of human trophoblast in a ligand-specific manner. J Clin Endocrinol Metab. 2000;85:3874–81.
103. Tarrade A, Schoonjans K, Guibourdenche J, Bidart JM, Vidaud M, Auwerx J, et al. PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology. 2001;142:4504–14.
104. Ceriello A, Johns D, Widel M, Eckland DJ, Gilmorfe KJ, Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care. 2005;28:266–72.
105. Chan L, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril. 2005;83:955–8.
106. Demissie Y, Fiad TM, Klemm K, Twfeeg A, Al-Amoudi A, Meer L, et al. Spontaneous singleton and twin pregnancy in two patients with polycystic ovary syndrome and type 2 diabetes following treatment with metformin combined with rosiglitazone. Ann Saudi Med. 2006;26:296–9.
107. Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol. 2011;74:332–9.
108. Ota H, Goto T, Yoshioka T, Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril. 2008;90:709–13.
109. McCarthy FP, Delany AC, Kenny LC, Walsh SK. PPAR-gamma—a possible drug target for complicated pregnancies. Br J Pharmacol. 2013;168:1074–85.
110. Zarate A, Ochoa R, Hernadez M, Basurto L. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy [in Spanish]. Ginecol Obstet Mex. 2000;68:42–5.
111. de Veciana M, Trail PA, Lau TK, Dulaney K. A comparison of oral acarbose and insulin in women with gestational diabetes mellitus. Obstet Gynecol. 2002;99(suppl):S5.
112. Hiles RA, Bawdon RE, Petrella EM. Ex vivo human placental transfer of the peptides pramlintide and exenatide. Hum Exp Toxicol. 2003;22:623–8.
113. Williams J, Pomeroy NE, Pop-Busui R, Lash R, Douyon L, Chames M, et al. Case report: exenatide use during pregnancy. Endocrinologist. 2009;19:119–21.